Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares US Real Estate ETF
IYR
|
+$947M |
| 2 |
Tesla
TSLA
|
+$608M |
| 3 |
Microsoft
MSFT
|
+$444M |
| 4 |
Accenture
ACN
|
+$409M |
| 5 |
iShares MSCI Emerging Markets ETF
EEM
|
+$396M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CRH
CRH
|
+$2.06B |
| 2 |
Texas Instruments
TXN
|
+$1.92B |
| 3 |
Meta Platforms (Facebook)
META
|
+$1.81B |
| 4 |
Starbucks
SBUX
|
+$1.42B |
| 5 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$1,000M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.52% |
| 2 | Financials | 7.13% |
| 3 | Consumer Discretionary | 6.46% |
| 4 | Healthcare | 5.43% |
| 5 | Communication Services | 5.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2176
PUT
Textron
TXT
$15.3B
| $4.43M | ﹤0.01% |
+50,000
| New | +$4.41M |
|
2177
Ultragenyx Pharmaceutical
RARE
$2.54B
| $4.42M | ﹤0.01% |
79,546
+16,633
| +26% | +$847K |
|
|
VRNT
2178
DELISTED
Verint Systems
VRNT
| $4.42M | ﹤0.01% |
174,335
-73,082
| -30% | -$2.25M |
|
|
PRO
2179
DELISTED
PROS Holdings
PRO
| $4.41M | ﹤0.01% |
238,382
+184,856
| +345% | +$3.9M |
|
2180
FB Financial Corp
FBK
$3.1B
| $4.41M | ﹤0.01% |
94,062
+34,633
| +58% | +$1.56M |
|
2181
Calix
CALX
$2.49B
| $4.41M | ﹤0.01% |
113,579
+73,588
| +184% | +$2.7M |
|
2182
Alpha Metallurgical Resources
AMR
$1.78B
| $4.4M | ﹤0.01% |
18,646
+14,089
| +309% | +$3.6M |
|
2183
CALL
Biogen
BIIB
$30.8B
| $4.4M | ﹤0.01% |
22,700
+9,200
| +68% | +$1.92M |
|
2184
iShares Core US Aggregate Bond ETF
AGG
$138B
| $4.4M | ﹤0.01% |
43,422
+43,341
| +53,507% | +$4.32M |
|
2185
Wolverine World Wide
WWW
$1.59B
| $4.37M | ﹤0.01% |
250,830
+221,904
| +767% | +$3.07M |
|
2186
Jazz Pharmaceuticals
JAZZ
$16.4B
| $4.37M | ﹤0.01% |
39,210
+6,289
| +19% | +$689K |
|
2187
CALL
eBay
EBAY
$48.7B
| $4.36M | ﹤0.01% |
67,000
| – | – |
|
2188
Kulicke & Soffa
KLIC
$4.91B
| $4.36M | ﹤0.01% |
96,604
+44,429
| +85% | +$1.96M |
|
2189
CALL
JFrog
FROG
$10.4B
| $4.36M | ﹤0.01% |
+150,000
| New | +$4.71M |
|
2190
Ligand Pharmaceuticals
LGND
$6.03B
| $4.35M | ﹤0.01% |
43,456
+7,247
| +20% | +$730K |
|
2191
Kymera Therapeutics
KYMR
$8.59B
| $4.34M | ﹤0.01% |
91,755
+42,662
| +87% | +$1.88M |
|
2192
MasterBrand
MBC
$1.21B
| $4.34M | ﹤0.01% |
234,160
+169,550
| +262% | +$2.76M |
|
2193
National Bank Holdings
NBHC
$1.94B
| $4.34M | ﹤0.01% |
103,076
+49,359
| +92% | +$2.05M |
|
2194
Hexcel
HXL
$7.88B
| $4.33M | ﹤0.01% |
70,023
+17,011
| +32% | +$1.07M |
|
2195
Uranium Energy
UEC
$5.2B
| $4.33M | ﹤0.01% |
697,045
+556,081
| +394% | +$3.02M |
|
2196
AAR Corp
AIR
$5.96B
| $4.33M | ﹤0.01% |
66,223
+48,298
| +269% | +$3.2M |
|
2197
OFG Bancorp
OFG
$2.26B
| $4.31M | ﹤0.01% |
96,045
+43,738
| +84% | +$1.88M |
|
2198
PUT
Carlyle Group
CG
$18.2B
| $4.31M | ﹤0.01% |
+100,000
| New | +$4.2M |
|
2199
Enterprise Financial Services Corp
EFSC
$2.44B
| $4.3M | ﹤0.01% |
83,910
+35,484
| +73% | +$1.74M |
|
2200
Red Rock Resorts
RRR
$3.76B
| $4.3M | ﹤0.01% |
78,932
+54,863
| +228% | +$3.05M |
|
Similar funds
Barclays's Q3 2024 Portfolio in Review
As of Q3 2024, Barclays held 5,593 positions worth $377B, up 15% from $327B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Barclays deployed $31.3B of net new capital in Q3 2024, opening 785 new positions and adding to 2,954 existing holdings. Its largest new stake was Smurfit Westrock: 3,460,710 shares worth $171M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 22% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was CRH, an estimated $2.06B trimmed.
- Barclays's largest Q3 2024 buy was Smurfit Westrock: 3,460,710 shares worth $171M.
- Barclays added most to iShares US Real Estate ETF in Q3 2024, an estimated $947M increase.
- Barclays's biggest Q3 2024 reduction was CRH, cutting an estimated $2.06B.
- Barclays fully exited Equitrans Midstream Corporation Common Stock in Q3 2024, selling an estimated $51.3M.
- Barclays's ten largest holdings make up 41% of its $377B portfolio in Q3 2024.
- Barclays opened 785 new positions and closed 322 in Q3 2024.
- Barclays's portfolio value rose 15% quarter-over-quarter to $377B.
Based on Barclays's 13F filing for Q3 2024, filed 15 Nov 2024.